VectorY broadens global PIONEER-ALS clinical trial cohort

VectorY Therapeutics has expanded the study size for its ongoing, global Phase I/II PIONEER-ALS clinical trial of VTx-002 for ALS. The post VectorY broadens global PIONEER-ALS clinical trial cohort appeared first on Clinical Trials Arena .